In This Issue
Cancer Discov January 1 2017 7 (1) 1-3; DOI:10.1158/2159-8290.CD-ITI7-1
CREBBP loss-of-function mutations accelerate lymphomagenesis by reducing H3K27 acetylation and allowing BCL6/SMRT/HDAC3-mediated repression of key GC B-cell enhancers.
BRN2 drives neuroendocrine differentiation and growth of androgen receptor–targeted prostate cancer.
Estrogen signaling in myeloid progenitor cells promotes myeloid-derived suppressor cell–mediated immuno-suppression and tumor progression, suggesting that estrogen antagonists may be effective in ER− tumors.
Mouse models show that TP53 and KEAP1 mutations drive squamous cell lung cancer growth and radioresistance.
Ipatasertib was well tolerated and resulted in disease control in a subset of patients with solid tumors, suggesting that ATP-competitive AKT inhibitors may have an improved safety profile compared with allosteric inhibitors.